Novo Nordisk's turoctocog close to Indian approval?
This article was originally published in Scrip
Executive Summary
Novo Nordisk's recombinant coagulation Factor VIII product NovoEight (turoctocog alfa) for haemophilia A appears to have inched closer to an approval in India after a key expert panel exempted it from local trial requirements.